Investigating Cooperation Between KEAP1 and LKB1 Inactivation in Lung Adenocarcinoma
Technical Report,01 Aug 2016,31 Jan 2019
DIGNITY HEALTH SAN FRANCISCO United States
Pagination or Media Count:
Preliminary analysis in our laboratory reveals concurrent mutation of the LKB1 and KEAP1 tumor suppressors correlate with poor overall survival in lung adenocarcinoma LA. Phenotypically, there is evidence to suggest that inactivation of KEAP1 may support adaptation to increased oxidative stress that results from LKB1 inactivation. We have found that inactivation of KEAP1 in the background of LKB1 inactivation results in increased growth and resistance to treatment. Further, we have evidence that cross-talk from the PERK kinase, may also further support adaptation to oxidative stress in combination with KEAP1 inactivation in LKB1-deficient LA. These findings suggest that KEAP1LKB1 inactivation may represent a critical step in LA tumorigenesis and may have a role in therapeutic resistance.
- Medicine and Medical Research